Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours

T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.

Citation:
Srinivasan S, Armitage J, Nilsson J, Waithman J. Transcriptional rewiring in CD8+ T cells: implications for CAR-T cell therapy against solid tumours. Front Immunol. 2024;15.

Keywords:
CAR-T cell; CD8+ T cell; adoptive cell therapy (ACT); cancer; immunotherapy; solid tumour; transcription factor

Abstract:
T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumours due to a range of barriers such as immunosuppression, poor infiltration, and tumour heterogeneity.